NIH seeks industry partners for technology transfer

June 23, 2022

The National Institutes of Health (NIH) is the world's largest public funder of biomedical research, investing more than $30 billion in taxpayer dollars. However, what is little known about the agency is that its technologies are available for licensing and collaboration, according to Michael Salgaller, PhD, supervisor of the technology analysis and marketing unit at the National Cancer Institute's (NCI) Technology Transfer Center.

ScienceBoard.net spoke with Salgaller at the 2022 Biotechnology Innovation Organization (BIO) International Convention about NIH's technology transfer professionals who work with its scientist inventors -- from basic science to translational to clinical -- to find commercial partners to take their inventions to market through licensing with hundreds of companies annually.

"There's a large percentage of our inventor portfolio that is unlicensed and we, at NIH, are not permitted to start companies. So, therefore, working with an industry partner to get that technology out of the lab bench to the clinic and to the marketplace is a must-have. It's not a nice-to-have," Salgaller said.

The Bayh-Dole Act of 1980 permits scientists, universities, and businesses to patent and profit from discoveries made through federally funded research. The law allows NIH to license technologies that were developed with public dollars. Salgaller notes that his office at NCI executes three licenses per week on average. To license from the agency, companies must have a commercialization plan in place for how they will get the technology to patients.

"We're not just interested in working with academia," Salgaller said. "The technologies that we've developed by our own scientists on our own campus are available for partnering and also for licensing."

Watch the video below to learn more.


Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net...
Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke...
Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and...
Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview...
Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid...
Struggle to include women in clinical trials continues despite gains
Though female participation in clinical trials has been steadily improving over the years, most of the women enrolled in trials are white and not members...
Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency...
How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke...
Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and...
The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have...
New era of non-viral DNA-delivered gene therapy seen emerging
Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in non-viral DNA-delivered gene therapy,...
Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense...
Biotech industry to gather at BIO International Convention in San Diego
More than 11,000 attendees from around the globe will be in San Diego, June 13-16, for the 2022 Biotechnology Innovation Organization (BIO) International...

Copyright © 2022 scienceboard.net

Last Updated 7/20/2022 2:28:45 PM